Who is affected and how:

• People who use or obtain tianeptine (including self-medication or nonprescription users) may face reduced legal availability and potential criminal exposure for unlawful possession or distribution. Individuals currently obtaining tianeptine without a lawful prescription or authorization will see access tightened.
• Retailers, online sellers, importers, and distributors of tianeptine products will need to stop or alter sales of uncontrolled forms or seek appropriate registrations and comply with Schedule III requirements; many existing sellers who market tianeptine as a supplement or research chemical will lose the ability to sell it without registration.
• Health care providers, pharmacists, and researchers handling tianeptine for legitimate medical or scientific purposes must obtain DEA registration, follow recordkeeping and security rules, and comply with prescribing/dispensing restrictions for Schedule III substances.
• Law enforcement and regulatory agencies will gain clear federal authority to investigate, seize, and prosecute illegal manufacture, distribution, or possession of tianeptine under federal controlled‑substance laws, and may coordinate with state actions that already regulate the substance.
• Manufacturers and labs developing or studying tianeptine will face additional regulatory compliance costs and timelines related to registration, secure handling, and reporting; some small vendors may discontinue products rather than register.

Overall, the change tightens federal control to reduce misuse and unregulated distribution, while imposing compliance obligations and potential criminal exposure for noncompliant sellers and users. It may reduce availability in commercial/online markets and increase administrative burdens for legitimate medical research and regulated supply chains.